HCC | Clinical

Chinese Study Finds That Sintilimab and Biosimilar Bevacizumab Prolong HCC PFS

July 23, 2021

Sintilimab in combination with the bevacizumab biosimilar, IBI305, is associated with a significant overall survival and progression-free survival benefit over sorafenib in the first-line setting for the treatment of Chinese patients with unresectable, hepatitis B virus-associated hepatocellular carcinoma.

Post Hoc Analysis Suggests Lenvatinib Therapy May Continue in Patients with Unresectable HCC, Child–Pugh class Liver Function

July 01, 2021

Patients with unresectable hepatocellular carcinoma with Child-Pugh class B liver function experienced a similar tumor size reduction as their Child-Pugh class A counterparts, all treated with lenvatinib, according to a post-hoc analysis of the phase 3 REFLECT study.